2017 American Transplant Congress
National Variation in US Kidney Transplant Induction Therapy.
Antibody induction (IND) therapy in kidney transplantation (KTx) reduces acute rejection risk but adds to transplant cost. Currently, only IL2 Receptor antibodies (IL2R-Ab) have FDA…2017 American Transplant Congress
Reassessing Thymoglobulin Induction in Kidney Transplantation (RETHINK): An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry.
There is no consensus on Thymoglobulin (TMG) dose used for induction immunosuppression (IS) in pediatric kidney transplants (KTx). We aimed to identify: 1) TMG induction…2017 American Transplant Congress
Induction Immunotherapy in ECD and DGF Kidneys: Does ECD Equal Diminishing Induction Returns?
University of Michigan, Ann Arbor
The benefit of induction immunotherapy to prevent DGF or mitigate its effects in recipients of marginal kidneys is not well understood and practices vary. We…2017 American Transplant Congress
Induction Therapy in Low Risk Elderly Kidney Transplant Recipients: Donor Factors.
Johns Hopkins, Baltimore; University of Colorado, Denver
It is not known whether depleting induction is needed in low-risk elderly kidney transplant (KT) recipients in whom concern for infectious and complications is higher…2017 American Transplant Congress
Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/kg vs. 6mg/kg in Kidney Transplant Patients Under Steroid-Free and CNI Minimization Maintenance Immunosuppressive Regimen.
Hospital Geral de Fortaleza, Fortaleza, Brazil
Background: rATG dosed from 4.5 to 7.5mg/kg has been the standard of care in most transplant centers. Recent studies have demonstrated similar efficacy with doses…2016 American Transplant Congress
Biopsies for Delayed Graft Function After Alemtuzumab Induction in Kidney Transplantation: The Incidence of Early Rejection After Alemtuzumab Is Very Low but Not Negligible.
IntroductionUK practice advocates transplant biopsy (Bx) at day 7, then weekly in the presence of delayed graft function (DGF) because if missed, early rejection adversely…2016 American Transplant Congress
Quality Assessment and Process Improvement of Thymoglobulin Dosing.
University of Minnesota, Minneapolis.
Thymoglobulin (Thymo) induction is given to prevent early rejection while initiating maintenance immunosuppression. Modification of dosing is common for multiple reasons. Our center recently underwent…2016 American Transplant Congress
Impact of Induction Therapy on Cardiovascular Events in Kidney Transplant Recipients.
1MUHC, Montreal, Canada; 2JHU, Baltimore.
Cardiovascular events (CVE) are one of leading causes of mortality in kidney transplant (KT) recipients and ATG use is reported as a risk factor. We…2016 American Transplant Congress
Surveillance Biopsy Findings with Alemtuzumab (ALZ) Induction in Kidney Transplantation.
The risk of subclinical histological changes in renal allografts with ALZ induction is not well defined. Hence, we performed a retrospective analysis of 527 surveillance…2016 American Transplant Congress
Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.
Transplantation, The University of Toledo, Toledo, OH.
Background: The highly successful induction drug Alemtuzumab (Campath) is commonly used prior to renal transplant. Yet, it does not completely ablate plasma cell which, in…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 31
- Next Page »